A recent study in a psychiatric hospital found that quetiapine was extensively used off-label in low doses and to treat depression or agitation or to sedate.

Quetiapine hasn’t been approved to treat insomnia by the FDA. However, due to its sedative effects, it’s still sometimes prescribed off-label as a short-term sleep aid.

Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in treatment-resistant depression, a study found.

In 2004, quetiapine, a second-generation dibenzothiazepine, received Food and Drug Administration (FDA) approval for use as monotherapy or adjunctive therapy for acute mania.

Quetiapine was also linked with lower costs (about $3,500 vs $4,100 for lithium) and larger gains in quality-adjusted life years (0.54 vs 0.47, respectively), the researchers reported in Lancet ...

A new study on the safety of the antipsychotic quetiapine in older patients found significantly greater instances of cognitive impairment associated with quetiapine over placebo.

Overall, 336 patients were assigned to the esketamine group and 340 to the quetiapine group. More patients in the esketamine group than in the quetiapine group had remission at week 8 (91 of 336 ...